140 related articles for article (PubMed ID: 35678328)
1. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
Raimondi A; Randon G; Prisciandaro M; Pagani F; Lonardi S; Antoniotti C; Bozzarelli S; Sartore-Bianchi A; Tampellini M; Fanchini L; Murialdo R; Clavarezza M; Zaniboni A; Berenato R; Ratti M; Petrelli F; Antonuzzo L; Giordano M; Rossi A; Di Bartolomeo M; Di Maio M; Pietrantonio F; Morano F
Int J Cancer; 2022 Nov; 151(10):1760-1769. PubMed ID: 35678328
[TBL] [Abstract][Full Text] [Related]
2. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
3. Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study.
Raimondi A; Fucà G; Leone AG; Lonardi S; Antoniotti C; Smiroldo V; Amatu A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Berenato R; Ratti M; Corallo S; Morano F; Di Bartolomeo M; Di Maio M; Pietrantonio F
ESMO Open; 2021 Oct; 6(5):100246. PubMed ID: 34416469
[TBL] [Abstract][Full Text] [Related]
4. Negative Hyperselection of Patients With
Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
[TBL] [Abstract][Full Text] [Related]
5. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.
Raimondi A; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Amatu A; Tampellini M; Racca P; Murialdo R; Clavarezza M; Zaniboni A; Toscano G; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Niger M; Antista M; Ambrosini M; Pagani F; Prisciandaro M; Randon G; de Braud F; Di Bartolomeo M; Pietrantonio F; Morano F
Support Care Cancer; 2021 Jul; 29(7):3971-3980. PubMed ID: 33392769
[TBL] [Abstract][Full Text] [Related]
6. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
Antonetti P; Fargnoli MC; Porzio G; Salvatore L; Filippi R; Ghidini M; Nigro O; Gelsomino F; Zurlo IV; Dell'Aquila E; Lombardi P; Keränen SR; Depetris I; Giampieri R; Morelli C; De Tursi M; Di Pietro FR; Zanaletti N; Vitale P; Garajova I; Spinelli GP; Zoratto F; Roberto M; Petrillo A; Aimar G; Cortellini A; Pensieri MV; Ficorella C; Ferri C; Parisi A
Support Care Cancer; 2022 Mar; 30(3):2455-2465. PubMed ID: 34779921
[TBL] [Abstract][Full Text] [Related]
7. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
8. Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
Manca P; Corallo S; Randon G; Lonardi S; Cremolini C; Rimassa L; Bergamo F; Antoniotti C; Smiroldo V; Zaniboni A; Murialdo R; Tampellini M; Tomasello G; Clavarezza M; Racca P; Antista M; Raimondi A; Prisciandaro M; Pagani F; Palermo F; Greco FG; Vaiani M; Di Bartolomeo M; de Braud F; Calareso G; Morano F; Pietrantonio F
Eur J Cancer; 2021 Feb; 144():31-40. PubMed ID: 33321462
[TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Raimondi A; Di Maio M; Morano F; Corallo S; Lonardi S; Antoniotti C; Rimassa L; Sartore-Bianchi A; Tampellini M; Ritorto G; Murialdo R; Clavarezza M; Zaniboni A; Adamo V; Tomasello G; Petrelli F; Antonuzzo L; Giordano M; Cinieri S; Longarini R; Bergamo F; Niger M; Antista M; Peverelli G; de Braud F; Di Bartolomeo M; Pietrantonio F
Eur J Cancer; 2020 Aug; 135():230-239. PubMed ID: 32623288
[TBL] [Abstract][Full Text] [Related]
11. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
[TBL] [Abstract][Full Text] [Related]
12. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
Lonardi S; Rasola C; Lobefaro R; Rossini D; Formica V; Scartozzi M; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Pella N; Bergamo F; Raimondi A; Arnoldi E; Antonuzzo L; Granetto C; Zustovich F; Ronzoni M; Leo S; Morano F; Loupakis F; Buggin F; Zagonel V; Fassan M; Cremolini C; Boni L; Pietrantonio F;
J Clin Oncol; 2023 Dec; 41(34):5263-5273. PubMed ID: 37535876
[TBL] [Abstract][Full Text] [Related]
13. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
15. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
16. Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212).
Heinrich K; Karthaus M; Fruehauf S; Graeven U; Mueller L; König AO; von Weikersthal LF; Caca K; Kretzschmar A; Goekkurt E; Haas S; Alig AHS; Kurreck A; Stahler A; Held S; Sommerhäuser G; Heinemann V; Stintzing S; Trarbach T; Modest DP
ESMO Open; 2023 Aug; 8(4):101568. PubMed ID: 37441876
[TBL] [Abstract][Full Text] [Related]
17. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Raimondi A; Nichetti F; Stahler A; Wasan HS; Aranda E; Randon G; Kurreck A; Meade AM; Díaz-Rubio E; Niger M; Stintzing S; Palermo F; Trarbach T; Prisciandaro M; Sommerhäuser G; Fisher D; Morano F; Pietrantonio F; Modest DP
Eur J Cancer; 2023 Sep; 190():112945. PubMed ID: 37441940
[TBL] [Abstract][Full Text] [Related]
18. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Watanabe J; Maeda H; Nagasaka T; Yokota M; Hirata K; Akazawa N; Kagawa Y; Yamada T; Shiozawa M; Ando T; Kato T; Mishima H; Sakamoto J; Oba K; Nagata N
Int J Cancer; 2022 Dec; 151(12):2172-2181. PubMed ID: 35723084
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.
Papamichael D; Lopes GS; Olswold CL; Douillard JY; Adams RA; Maughan TS; Van Cutsem E; Venook AP; Lenz HJ; Heinemann V; Kaplan R; Bokemeyer C; Chibaudel B; Grothey A; Yoshino T; Zalcberg J; De Gramont A; Shi Q
Eur J Cancer; 2022 Mar; 163():1-15. PubMed ID: 35033994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
